LivaNova - LIVN Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIVN shares.
View LIVN analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price targets for LivaNova's shares. Their LIVN share price forecasts range from $63.00 to $96.00. On average, they expect the company's share price to reach $83.00 in the next year. This suggests a possible upside of 58.4% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.

LivaNova's stock was trading at $87.43 on January 1st, 2022. Since then, LIVN shares have decreased by 40.1% and is now trading at $52.40.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our LIVN earnings forecast.

LivaNova PLC (NASDAQ:LIVN) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.01. The firm earned $252.60 million during the quarter, compared to the consensus estimate of $246.53 million. LivaNova had a positive trailing twelve-month return on equity of 9.28% and a negative net margin of 9.14%.

LivaNova updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $2.25-$2.45 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of $1.08 billion-$1.10 billion, compared to the consensus revenue estimate of $1.01 billion.

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

LivaNova's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.99%), Primecap Management Co. CA (8.55%), State Street Corp (4.78%), Barrow Hanley Mewhinney & Strauss LLC (4.56%), Eminence Capital LP (3.90%) and Dimensional Fund Advisors LP (1.93%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends.

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LIVN stock can currently be purchased for approximately $52.40.

LivaNova (NASDAQ:LIVN) has a market capitalization of $2.80 billion and generates $1.04 billion in revenue each year. The company earns $-135,820,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

The company employs 3,000 workers across the globe.

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.